These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 14651494)

  • 1. The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings.
    McCollister KE; French MT
    Addiction; 2003 Dec; 98(12):1647-59. PubMed ID: 14651494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
    French MT; Salomé HJ; Carney M
    Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness of addiction care].
    Suijkerbuijk AW; van Gils PF; Greeven PG; de Wit GA
    Tijdschr Psychiatr; 2015; 57(7):498-507. PubMed ID: 26189418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Legislations and policies to expand mental health and substance abuse benefits in health insurance plans: a community guide systematic economic review.
    Jacob V; Qu S; Chattopadhyay S; Sipe TA; Knopf JA; Goetzel RZ; Finnie R; Thota AB;
    J Ment Health Policy Econ; 2015 Mar; 18(1):39-48. PubMed ID: 25862203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes.
    Sindelar JL; Jofre-Bonet M; French MT; McLellan AT
    Drug Alcohol Depend; 2004 Jan; 73(1):41-50. PubMed ID: 14687958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The costs of crime and the benefits of substance abuse treatment for pregnant women.
    Daley M; Argeriou M; McCarty D; Callahan JJ; Shepard DS; Williams CN
    J Subst Abuse Treat; 2000 Dec; 19(4):445-58. PubMed ID: 11166509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.
    French MT; Salomé HJ; Sindelar JL; McLellan AT
    Health Serv Res; 2002 Apr; 37(2):433-55. PubMed ID: 12036002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic benefits of substance use disorder treatment: A systematic literature review of economic evaluation studies from 2003 to 2021.
    Fardone E; Montoya ID; Schackman BR; McCollister KE
    J Subst Use Addict Treat; 2023 Sep; 152():209084. PubMed ID: 37302488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit-cost analysis of addiction treatment in Arkansas: specialty and standard residential programs for pregnant and parenting women.
    French MT; McCollister KE; Cacciola J; Durell J; Stephens RL
    Subst Abus; 2002 Mar; 23(1):31-51. PubMed ID: 12444359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"?
    Ettner SL; Huang D; Evans E; Ash DR; Hardy M; Jourabchi M; Hser YI
    Health Serv Res; 2006 Feb; 41(1):192-213. PubMed ID: 16430607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Out of touch or on the money: Do the clinical objectives of addiction treatment coincide with economic evaluation results?
    Dismuke CE; French MT; Salomé HJ; Foss MA; Scott CK; Dennis ML
    J Subst Abuse Treat; 2004 Oct; 27(3):253-63. PubMed ID: 15501378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating primary medical care with addiction treatment: a randomized controlled trial.
    Weisner C; Mertens J; Parthasarathy S; Moore C; Lu Y
    JAMA; 2001 Oct; 286(14):1715-23. PubMed ID: 11594896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic benefits of substance abuse treatment: findings from Cuyahoga County, Ohio.
    Koenig L; Siegel JM; Harwood H; Gilani J; Chen YJ; Leahy P; Stephens R
    J Subst Abuse Treat; 2005; 28 Suppl 1():S41-50. PubMed ID: 15797638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Public expenditure caused by the consumption of illicit drugs in Germany].
    Mostardt S; Flöter S; Neumann A; Wasem J; Pfeiffer-Gerschel T
    Gesundheitswesen; 2010 Dec; 72(12):886-94. PubMed ID: 20066613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monetary conversion factors for economic evaluations of substance use disorders.
    McCollister K; Yang X; Sayed B; French MT; Leff JA; Schackman BR
    J Subst Abuse Treat; 2017 Oct; 81():25-34. PubMed ID: 28847452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit-cost analysis of brief physician advice with problem drinkers in primary care settings.
    Fleming MF; Mundt MP; French MT; Manwell LB; Stauffacher EA; Barry KL
    Med Care; 2000 Jan; 38(1):7-18. PubMed ID: 10630716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the differential costs of criminal activity for juvenile drug court participants: challenges and recommendations.
    McCollister KE; French MT; Sheidow AJ; Henggeler SW; Halliday-Boykins CA
    J Behav Health Serv Res; 2009 Jan; 36(1):111-26. PubMed ID: 18172769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Training the next generation of providers in addiction medicine.
    Rasyidi E; Wilkins JN; Danovitch I
    Psychiatr Clin North Am; 2012 Jun; 35(2):461-80. PubMed ID: 22640766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of time in treatment on the employment and earnings of drug abusers.
    French MT; Zarkin GA; Hubbard RL; Rachal JV
    Am J Public Health; 1991 Jul; 81(7):904-7. PubMed ID: 1905111
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.